Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy BioPharma Dive
Multiple Myeloma News
Multiple Myeloma Drug Candidate Advances to Phase 2 Trials - Technology Networks
Multiple Myeloma Drug Candidate Advances to Phase 2 Trials Technology Networks
Pharmacists Weigh Real-World Challenges of Bispecific Antibodies in Multiple Myeloma - Pharmacy Times
Pharmacists Weigh Real-World Challenges of Bispecific Antibodies in Multiple Myeloma Pharmacy Times
How Does KTX-1001 Target Genetic Abnormalities in Multiple Myeloma? - CancerNetwork
How Does KTX-1001 Target Genetic Abnormalities in Multiple Myeloma? CancerNetwork
C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma - Clinical Trials Arena
C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma Clinical Trials Arena
Gilead to buy Arcellx in nearly $8B deal - statnews.com
Gilead to buy Arcellx in nearly $8B deal statnews.com
Updated: Gilead to buy cell therapy partner Arcellx in deal valued at $7.8B - Endpoints News
Updated: Gilead to buy cell therapy partner Arcellx in deal valued at $7.8B Endpoints News
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition BioSpace
This cancer is stubborn, but new drug regimen shows promise - The Washington Post
This cancer is stubborn, but new drug regimen shows promise The Washington Post
AF Common, Worsens Prognosis After Stem Cell Transplant for Multiple Myeloma - TCTMD.com
AF Common, Worsens Prognosis After Stem Cell Transplant for Multiple Myeloma TCTMD.com
FDA reviewing new iberdomide combination for multiple myeloma - Rare Cancer News
FDA reviewing new iberdomide combination for multiple myeloma Rare Cancer News
Endogenous T-Cell Activation Has Potential Role After CAR T in Myeloma - Targeted Oncology
Endogenous T-Cell Activation Has Potential Role After CAR T in Myeloma Targeted Oncology
Multiple Myeloma and Blood Clots: What to know - Healthline
Multiple Myeloma and Blood Clots: What to know Healthline
Dr Kaur on the Potential Effect of CELMoDs on Multiple Myeloma Management - OncLive
Dr Kaur on the Potential Effect of CELMoDs on Multiple Myeloma Management OncLive
Phase 2 Trial Begins Dosing of Cemsidomide Combo in R/R Multiple Myeloma - CancerNetwork
Phase 2 Trial Begins Dosing of Cemsidomide Combo in R/R Multiple Myeloma CancerNetwork
Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates - Yahoo Finance
Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates Yahoo Finance
Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal - MedCity News
Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal MedCity News
Gilead's $7.8 Billion Bet on Arcellx: A New Era for Multiple Myeloma Therapy Begins - Investing News Network
Gilead's $7.8 Billion Bet on Arcellx: A New Era for Multiple Myeloma Therapy Begins Investing News Network
Breakthrough multiple myeloma drug shows promise in early trial - Open Access Government
Breakthrough multiple myeloma drug shows promise in early trial Open Access Government
Cryo-EM Reveals Light Chain Fibrils in Myeloma - BIOENGINEER.ORG
Cryo-EM Reveals Light Chain Fibrils in Myeloma BIOENGINEER.ORG
Navigating the Later-Line Landscape: Insights from the MajesTEC-1 Trial - Targeted Oncology
Navigating the Later-Line Landscape: Insights from the MajesTEC-1 Trial Targeted Oncology
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy - Yahoo Finance
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy Yahoo Finance
Gilead to buy Arcellx in $7.8bn deal to advance multiple myeloma treatment - BioXconomy
Gilead to buy Arcellx in $7.8bn deal to advance multiple myeloma treatment BioXconomy
Gilead inks $8B Arcellx buyout to steer CAR-T into J&J showdown - Fierce Biotech
Gilead inks $8B Arcellx buyout to steer CAR-T into J&J showdown Fierce Biotech
Multiple Myeloma: Improved Prognosis With the Latest Treatments - Memorial Sloan Kettering Cancer Center
Multiple Myeloma: Improved Prognosis With the Latest Treatments Memorial Sloan Kettering Cancer Center
It's hard to predict life expectancy with multiple myeloma - Rare Cancer News
It's hard to predict life expectancy with multiple myeloma Rare Cancer News
ASH 2025: New Combinations Drive Advances in Multiple Myeloma - Cancer Therapy Advisor
ASH 2025: New Combinations Drive Advances in Multiple Myeloma Cancer Therapy Advisor
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline - GEN - Genetic Engineering and Biotechnology News
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline GEN - Genetic Engineering and Biotechnology News
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial - University of Miami
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial University of Miami
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx Pharmaceutical Executive
Samer Al Hadidi: What Long-Term Data Reveal About Cure in Multiple Myeloma - Oncodaily
Samer Al Hadidi: What Long-Term Data Reveal About Cure in Multiple Myeloma Oncodaily
2 multiple myeloma treatments receive FDA approval - michiganmedicine.org
2 multiple myeloma treatments receive FDA approval michiganmedicine.org
Diagnosis, risk stratification and management of smouldering multiple myeloma - Nature
Diagnosis, risk stratification and management of smouldering multiple myeloma Nature
Gilead Sciences Acquires Arcellx - Contract Pharma
Gilead Sciences Acquires Arcellx Contract Pharma
Committed Care Team Explores Every Avenue Possible to Treat Young Woman's Multiple Myeloma - Mass General Brigham
Committed Care Team Explores Every Avenue Possible to Treat Young Woman's Multiple Myeloma Mass General Brigham
Myeloma Paper of the Day, February 23th, Suggested by Robert Orlowski - Oncodaily
Myeloma Paper of the Day, February 23th, Suggested by Robert Orlowski Oncodaily
Cynthia Chmielewski: What “Cure” Will Mean in Myeloma - Oncodaily
Cynthia Chmielewski: What “Cure” Will Mean in Myeloma Oncodaily
Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion - Reuters
Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion Reuters
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma - Nature
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma Nature
Inflammatory immune cells predict survival, relapse in multiple myeloma - WashU Medicine
Inflammatory immune cells predict survival, relapse in multiple myeloma WashU Medicine